PE20231054A1 - Metodo para tratamiento del cancer cervicouterino - Google Patents
Metodo para tratamiento del cancer cervicouterinoInfo
- Publication number
- PE20231054A1 PE20231054A1 PE2022002454A PE2022002454A PE20231054A1 PE 20231054 A1 PE20231054 A1 PE 20231054A1 PE 2022002454 A PE2022002454 A PE 2022002454A PE 2022002454 A PE2022002454 A PE 2022002454A PE 20231054 A1 PE20231054 A1 PE 20231054A1
- Authority
- PE
- Peru
- Prior art keywords
- cervical cancer
- treatment
- seq
- hpv
- vaccine
- Prior art date
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title abstract 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title abstract 2
- 201000010881 cervical cancer Diseases 0.000 title abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 229960002566 papillomavirus vaccine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Communicable Diseases (AREA)
Abstract
Referido a una composicion farmaceutica, caracterizada porque comprende una vacuna contra el virus del papiloma humano (HPV) y un agente inhibidor de puntos de control; en donde la vacuna contra el HPV comprende el polinucleotido de la SEC ID NO: 15 o una variante funcional con una identidad de secuencia del 85 % o mas con la SEC ID NO: 15. Tambien se refiere a un metodo para tratamiento del cancer cervicouterino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063015076P | 2020-04-24 | 2020-04-24 | |
PCT/KR2021/005237 WO2021215896A1 (en) | 2020-04-24 | 2021-04-26 | Method for treating cervical cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231054A1 true PE20231054A1 (es) | 2023-07-11 |
Family
ID=78221098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002454A PE20231054A1 (es) | 2020-04-24 | 2021-04-26 | Metodo para tratamiento del cancer cervicouterino |
Country Status (14)
Country | Link |
---|---|
US (1) | US11883479B2 (es) |
EP (1) | EP4138900A4 (es) |
JP (1) | JP7460094B2 (es) |
KR (2) | KR20240029786A (es) |
CN (1) | CN115551547A (es) |
AU (1) | AU2021261676A1 (es) |
BR (1) | BR112022021284A2 (es) |
CA (1) | CA3176240A1 (es) |
CO (1) | CO2022016810A2 (es) |
IL (1) | IL297502A (es) |
MX (1) | MX2022013063A (es) |
PE (1) | PE20231054A1 (es) |
WO (1) | WO2021215896A1 (es) |
ZA (1) | ZA202211410B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023172036A1 (ko) * | 2022-03-10 | 2023-09-14 | 주식회사 제넥신 | 두경부암 치료를 위한 삼중 복합약물 투여요법 |
WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
KR100201584B1 (ko) | 1996-07-12 | 1999-06-15 | 손경식 | 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
EP2100620A1 (en) | 1999-09-16 | 2009-09-16 | Eisai Corporation of North America | Nucleic acids encoding polyepitope polypeptides |
ATE354662T1 (de) | 2001-03-23 | 2007-03-15 | Deutsches Krebsforsch | Modifizierte hpv e6- und e7-gene und -proteine als impfstoff |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
DK1553966T3 (da) | 2002-10-03 | 2012-09-17 | Wyeth Corp | Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf |
CN1299769C (zh) | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
EP1757615B1 (en) | 2005-08-24 | 2011-08-24 | Healthbanks Biotech Co., Ltd. | Fusion protein for inhibiting cervical cancer |
US7732166B2 (en) | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
JP5345053B2 (ja) | 2006-04-19 | 2013-11-20 | 浦項工科大學校 産學協力團 | 子宮頸癌の予防及び治療のためのヒトパピローマウイルスポリペプチドと免疫増強剤を含む組成物 |
WO2008046251A1 (fr) * | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
DE102008010954A1 (de) | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
EP2377879A1 (en) | 2010-04-14 | 2011-10-19 | Deutsches Krebsforschungszentrum | N-terminal HPV E7 fusion proteins |
WO2012020871A1 (ko) | 2010-08-13 | 2012-02-16 | 주식회사 제넥신 | 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물 |
CA2858963C (en) | 2011-12-21 | 2023-05-23 | Vaccibody As | Vaccines against hpv |
HUE044430T2 (hu) * | 2013-03-01 | 2019-10-28 | Astex Pharmaceuticals Inc | Gyógyszerkombinációk |
CN107073070A (zh) | 2014-08-15 | 2017-08-18 | 格纳西尼有限公司 | 治疗宫颈癌的方法 |
MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
US20180250378A1 (en) * | 2017-03-03 | 2018-09-06 | Papivax Biotech Inc. | Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases |
WO2018175676A1 (en) | 2017-03-23 | 2018-09-27 | The General Hospital Corporation | Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease |
-
2021
- 2021-04-26 US US17/240,224 patent/US11883479B2/en active Active
- 2021-04-26 IL IL297502A patent/IL297502A/en unknown
- 2021-04-26 CN CN202180030597.2A patent/CN115551547A/zh active Pending
- 2021-04-26 BR BR112022021284A patent/BR112022021284A2/pt unknown
- 2021-04-26 PE PE2022002454A patent/PE20231054A1/es unknown
- 2021-04-26 CA CA3176240A patent/CA3176240A1/en active Pending
- 2021-04-26 EP EP21793447.0A patent/EP4138900A4/en active Pending
- 2021-04-26 AU AU2021261676A patent/AU2021261676A1/en active Pending
- 2021-04-26 MX MX2022013063A patent/MX2022013063A/es unknown
- 2021-04-26 WO PCT/KR2021/005237 patent/WO2021215896A1/en active Application Filing
- 2021-04-26 KR KR1020247005905A patent/KR20240029786A/ko active Application Filing
- 2021-04-26 JP JP2022564262A patent/JP7460094B2/ja active Active
- 2021-04-26 KR KR1020227022552A patent/KR20220109444A/ko active Application Filing
-
2022
- 2022-10-18 ZA ZA2022/11410A patent/ZA202211410B/en unknown
- 2022-11-23 CO CONC2022/0016810A patent/CO2022016810A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4138900A1 (en) | 2023-03-01 |
KR20220109444A (ko) | 2022-08-04 |
US11883479B2 (en) | 2024-01-30 |
WO2021215896A1 (en) | 2021-10-28 |
US20210330779A1 (en) | 2021-10-28 |
BR112022021284A2 (pt) | 2022-12-06 |
EP4138900A4 (en) | 2024-05-15 |
AU2021261676A1 (en) | 2022-11-24 |
CA3176240A1 (en) | 2021-10-28 |
KR20240029786A (ko) | 2024-03-06 |
CO2022016810A2 (es) | 2023-02-27 |
CN115551547A (zh) | 2022-12-30 |
MX2022013063A (es) | 2022-12-08 |
IL297502A (en) | 2022-12-01 |
JP2023522989A (ja) | 2023-06-01 |
JP7460094B2 (ja) | 2024-04-02 |
ZA202211410B (en) | 2024-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231054A1 (es) | Metodo para tratamiento del cancer cervicouterino | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
AR105712A1 (es) | Composiciones de insulina de rápida acción | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
MX2021002321A (es) | Nuevos metodos. | |
MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
MX2022012692A (es) | Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas. | |
CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
AR124639A1 (es) | Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión | |
MX2020013601A (es) | Receptores de las celulas t especificos de cancer. | |
CL2021001096A1 (es) | Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) | |
BR112021023319A2 (pt) | Vetor viral | |
CL2018002438A1 (es) | Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. | |
AR111699A1 (es) | Composición farmacéutica que comprende betahistina | |
PE20221731A1 (es) | NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV | |
PH12021550417A1 (en) | Compositions and methods for controlled ovarian stimulation | |
Kim et al. | Clinical study of twenty-seven case of treating acne scar using microneedle therapy and subcision combined with Beevenom pharmacopuncture therapy | |
BR112021020141A2 (pt) | Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva | |
BR112019012057A2 (pt) | agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv) | |
BR112015028334A2 (pt) | agente e método para o tratamento de herpes | |
MX2020004518A (es) | Suministro asistido de manera magnética al interior y a través de la piel. | |
PE20211376A1 (es) | Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham |